ArticleWorld journal of experimental medicine2025
Burden of multi-drug-resistant organisms in a tertiary healthcare institute in North India: Implications for regional public health.
Article in World journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Carbapenem-resistant and other multidrug-resistant organisms in a South Indian tertiary care centre: A laboratory-based study.The Indian journal of medical research · 2026Article
- Article
- The Multifaceted Mechanistic Actions of Antimicrobial Nanoformulations: Overcoming Resistance and Enhancing Efficacy.Pharmaceutics · 2026Review
- Risk Factors and Medical Burden of Multidrug-Resistant Organism Infection in Hospitalized Patients with Pneumonia.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance (AMR) is an escalating global health threat, disproportionately impacting low-income and middle-income countries like India. The rise of multidrug-resistant organisms (MDROs) complicates treatment, increases healthcare costs, and contributes to higher morbidity and mortality. In India, factors such as antibiotic misuse, over-the-counter availability, and self-medication have exacerbated this crisis. Despite the urgency, regional data on MDRO prevalence remains limited.
aimTo assess the burden and distribution of MDRO infections identified at a tertiary healthcare institute in North India.
methodsThis cross-sectional study analyzed inpatient data from All India Institute of Medical Sciences (AIIMS) Rishikesh using the E-hospital database from May 2021 to February 2024, except 2022. All inpatients with culture-confirmed MDRO infections were included. Patient charts and discharge summaries were reviewed. Data analysis was performed using Jamovi software, with descriptive statistics summarizing demographics. The
resultsThis study included 820 participants having 1106 MDROs. The majority of patients were aged 35-64 years, with a male predominance (57.6%). Most cases were from Uttar Pradesh (49.1%) and Uttarakhand (47.6%), with Bijnor and Haridwar districts reporting the highest burden from their respective states.
conclusionThis study highlights the burden of MDROs among patients at AIIMS Rishikesh, with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.